2023-05-09 07:10:23 ET
- Voyager Therapeutics press release ( NASDAQ: VYGR ): Q1 GAAP EPS of $2.94 beats by $1.90 .
- Revenue of $150.48M (+22700.0% Y/Y) beats by $97.98M .
- Cash, cash equivalents and marketable securities as of March 31, 2023, were $273.3 million. Cash position does not include $25.0 million in option exercise payment from Novartis which was received after March 31, 2023.
- Outlook: As communicated previously, the Company expects its cash, cash equivalents, and marketable securities, together with the $25.0 million options exercise payment received in April 2023 from Novartis, along with amounts expected to be received as reimbursement for development costs under the Neurocrine collaborations, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2025.
- Shares -0.78% PM.
For further details see:
Voyager Therapeutics GAAP EPS of $2.94 beats by $1.90, revenue of $150.48M beats by $97.98M